H1 19: disproportionate growth in EBIT
08/08/19 -"The H1 19 performance was neither outstanding nor bad but was blurred by IFRS 16, the sale of a 49% stake in Aqualia and lower sales of CO2 emission rights. Overall, following this earnings ..."
Pages
67
Language
English
Published on
08/08/19
You may also be interested by these reports :
12/04/24
We have updated certain assumptions on 2024 and 2025 that seemed overly pessimistic compared to the group’s guidance, particularly regarding the ...
09/04/24
In our opinion, EDP’s valuation is impacted by its aggressive farm-down strategy and the high proportion of minority interests amounting to 30% on ...
04/04/24
According to the Australian Financial Review, Neoen has engaged Bank of America to facilitate the sale of 30% of its Australian portfolio for ...
02/04/24
Our EPS has been revised upwards due to a reduction in financial expenses. Centrica has accumulated a net cash position of £2.7bn, enabling it to ...